ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Down 12.8% in November

ANI Pharmaceuticals, Inc. (NASDAQ:ANIPGet Free Report) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 1,840,000 shares, a decline of 12.8% from the November 15th total of 2,110,000 shares. Based on an average daily volume of 292,900 shares, the short-interest ratio is presently 6.3 days.

ANI Pharmaceuticals Stock Down 0.4 %

ANIP opened at $56.36 on Tuesday. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals has a 12 month low of $51.88 and a 12 month high of $70.81. The stock has a market capitalization of $1.19 billion, a P/E ratio of -102.47 and a beta of 0.73. The business has a 50 day simple moving average of $58.02 and a 200-day simple moving average of $60.24.

ANI Pharmaceuticals (NASDAQ:ANIPGet Free Report) last issued its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.09 by $0.25. The company had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business’s revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.05 EPS. On average, equities analysts anticipate that ANI Pharmaceuticals will post 3.87 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Nikhil Lalwani sold 33,481 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the sale, the chief executive officer now owns 370,378 shares in the company, valued at approximately $21,478,220.22. The trade was a 8.29 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the senior vice president now owns 49,059 shares of the company’s stock, valued at $2,943,540. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,731 shares of company stock worth $2,015,861. Corporate insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently modified their holdings of the company. State Street Corp increased its stake in ANI Pharmaceuticals by 9.1% in the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock valued at $41,991,000 after purchasing an additional 58,698 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of ANI Pharmaceuticals by 3.5% in the second quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company’s stock valued at $40,132,000 after buying an additional 21,053 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of ANI Pharmaceuticals by 23,259.8% during the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock worth $33,907,000 after buying an additional 565,910 shares during the last quarter. Global Alpha Capital Management Ltd. boosted its position in shares of ANI Pharmaceuticals by 1.8% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after buying an additional 9,500 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in ANI Pharmaceuticals by 4.2% in the 3rd quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock valued at $25,373,000 after acquiring an additional 17,314 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ANIP. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Truist Financial increased their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Raymond James upped their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price on the stock. Finally, Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

Read Our Latest Stock Analysis on ANIP

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

Featured Articles

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.